Zydus Lifesciences. has filed a patent for a liquid oral formulation containing 10 mg/mL of sildenafil citrate and glycerin as a wetting agent. The formulation is designed for the treatment of conditions like pulmonary arterial hypertension and erectile dysfunction. GlobalData’s report on Zydus Lifesciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Zydus Lifesciences Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zydus Lifesciences, NSAID cancer drugs was a key innovation area identified from patents. Zydus Lifesciences's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20230381187A1) discloses a ready-to-use liquid oral formulation containing sildenafil citrate at a concentration of about 10 mg/mL, along with pharmaceutically acceptable excipients including a wetting agent like glycerin. The formulation is specified to have a pH ranging from about 4 to 8, with variations in pH levels mentioned in specific claims. Additionally, the formulation may include a buffering agent and anti-foaming agent, along with sildenafil citrate particles and a viscosity-modifying agent comprising water-soluble hydrocolloids.

Furthermore, the patent application outlines methods of treating various conditions in humans by administering the disclosed liquid oral formulation. The conditions mentioned include hypertension, pulmonary hypertension, arterial hypertension, pulmonary arterial hypertension, and erectile dysfunction. The stability of the formulation is highlighted, indicating that it remains stable for up to six months when stored under specific conditions. The presence of impurities in the composition is also limited to ensure product quality and efficacy in treating the specified conditions.

To know more about GlobalData’s detailed insights on Zydus Lifesciences, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies